Treatment modifiers across different regimens of natalizumab treatment in MS: An Italian real-world experience-Reference-Cited by-同舟云学术

Treatment modifiers across different regimens of natalizumab treatment in MS: An Italian real-world experience

Published:2024-04 Issue:3 Volume:21 Page:e00338
ISSN:1878-7479
Container-title:Neurotherapeutics
language:en
Short-container-title:Neurotherapeutics

Author:

Ruggieri Serena,Ianniello Antonio,Copetti Massimiliano,Altieri Marta,Buscarinu Maria Chiara,Centonze Diego,Cortese Antonio,De Giglio Laura,Fantozzi Roberta,Gasperini Claudio,Grimaldi Luigi M.E.,Landi Doriana,Marfia Girolama A.,Mirabella Massimiliano,Nistri Riccardo,Nociti Viviana,Oddo Oscar,Romano Silvia,Salemi Giuseppe,Tortorella Carla,Pozzilli Carlo,Petracca Maria

Funder

Istituto Italiano di Tecnologia

Biogen Inc

Publisher

Elsevier BV

Reference30 articles.

1. Long- term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real- world data from the Tysabri Observational Program (TOP);Butzkueven;J Neurol Neurosurg Psychiatry,2020

2. Disease - modifying therapies for relapsing – remitting multiple sclerosis : a network meta - analysis;Lucchetta;CNS Drugs,2018

3. Risk of natalizumab-associated progressive multifocal leukoencephalopathy;Bloomgren;N Engl J Med,2012

4. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing;Ryerson;Neurology,2019

5. Pharmacodynamics of natalizumab extended interval dosing in MS;Ryerson;Neurol - Neuroimmunol Neuroinflammation.,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Extended interval dosing of natalizumab: More evidence in support;Neurotherapeutics;2024-04